Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00602407
NCT00602407CompletedNot Applicable

A Single Dose, Randomized, Two-Period, Two-Treatment, Crossover Bioequivalency Study of Cilostazol 50 mg Tablets Under Fasting Conditions

Roxane Laboratories1 site in 1 country36 target enrollmentStarted: February 1, 2004Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
36
Locations
1
Primary Endpoint
Bioequivalence
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 50 mg, to PLETAL® Tablets, 50 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, crossover design.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria

  • •Positive test for HIV, Hepatitis B, or Hepatitis C.
  • •Treatment with known enzyme altering drugs.
  • •History of allergic or adverse response to Cilostazol or any comparable or similar product.

Outcomes

Primary Outcomes

Bioequivalence

Time Frame: Baseline, Two period, Seven day washout

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting ConditionsIntermittent Claudication
NCT00602173Roxane Laboratories32
Completed
Phase 1
Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed ConditionsTrichomoniasis
NCT01591889Roxane Laboratories28
Completed
Not Applicable
Bioequivalency Study of Meloxicam Tablets Under Fasting ConditionsInflammation
NCT00618163Roxane Laboratories47
Completed
Not Applicable
Bioequivalency Study of Meloxicam Tablets Under Fed ConditionsInflammation
NCT00601887Roxane Laboratories48
Completed
Not Applicable
Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed ConditionsShort Term Treatment of Insomnia
NCT00694317Roxane Laboratories40